Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen
Accession Number
DB10774
Description

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Recombinant
Synonyms
  • influenza A virus A/Victoria/361/2011 (H3N2) antigen

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
FlublokInfluenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen (45 ug/0.5mL) + Influenza A virus A/California/7/2009 (H1N1) recombinant hemagglutinin antigen (45 ug/0.5mL) + Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen (45 ug/0.5mL)Injection, solutionIntramuscularProtein Sciences Corporation2013-02-012013-06-30US flag

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
K5313H4VGS
CAS number
Not Available

References

General References
Not Available
RxNav
1663632

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingBasic ScienceFlu caused by Influenza1
4Active Not RecruitingPreventionFlu caused by Influenza1
4Active Not RecruitingPreventionFlu caused by Influenza / Influenza, Human / Influenza-like illness or flu-like symptoms1
4CompletedBasic ScienceFlu Vaccine1
4RecruitingBasic ScienceFlu caused by Influenza1
4RecruitingPreventionInfluenza, Human / Novel Coronavirus Infectious Disease (COVID-19)1
3CompletedPreventionFlu caused by Influenza5
2, 3CompletedPreventionFlu caused by Influenza1
1Active Not RecruitingTreatmentHead and Neck Carcinoma / Head and Neck Squamous Cell Carcinoma (HNSCC)1
1, 2CompletedPreventionFlu caused by Influenza1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 13:04 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates